Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and ...

Compass Pathways (NASDAQ:CMPS) executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...

Definium Therapeutics is expecting late-stage data for two anxiety trials in the coming months, teeing up a potential ...

Despite this, the Food and Drug Administration didn’t formally review a psychedelic compound for federal regulation until ...

With one approved drug (Johnson & Johnson’s Spavaro) already doing $468 million per quarter in sales, and with companies like ...

AtaiBeckley (NasdaqGM: ATAI) reported peer reviewed Phase 2a results for its BPL-003 program in treatment resistant depression. The study showed a rapid and sustained antidepressant response from a ...

Propel Holdings Inc. ("Propel") , the fintech facilitating access to credit for underserved consumers, announced today that it will be reporting financial results for the three months ending March 31, ...

Valmet's Interim Review January - March 2026 will be published on Tuesday, April 28, 2026, at approximately 9:00 a.m. Finnish time (EEST). The stock exchange release and presentation materials will be ...

SB83 ensures that when the federal government approves and reschedules a new medication, Utah follows suit immediately. This ...

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not ...